Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID
Medicines For Europe And IGBA Set Out Policy Priorities At Athens Conference
Executive Summary
Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.
You may also be interested in...
Jonathan Kimball Named IGBA Chair For 2023
The IGBA chair passes to Jonathan Kimball. He will head the global off-patent industry organization as it steps up its activities in global policy.
Stampa Urges Investment In European Manufacturing
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.
IGBA Appoints Frittelli As 2022 Chair
The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.